nach oben

Tumor Biology

Erschienen in:

12.11.2015 | Original Article

miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma

verfasst von: Can Shi, Zhenyu Zhang

Erschienen in: Tumor Biology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Increasing evidences have revealed that microRNAs regulate various biological processes. However, the roles of miR-761 have not been investigated in ovarian cancer. Here, we found that miR-761 expression was significantly lower in ovarian cancer tissues than in their paired noncancerous tissues. Further study revealed that miR-761 overexpression inhibited the ovarian cancer cell proliferation and invasion. Mechanistically, we demonstrated that the oncogenic properties of miR-761 in ovarian cancer were mediated in part by regulating MSI1 expression. miR-761 and MSI1 are inversely expressed in ovarian cancer tissues. In conclusion, we demonstrated that miR-761 repressed ovarian cancer proliferation and invasion by targeting MSI1.

Luo X, Dong Z, Chen Y, Yang L, Lai D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013;46:436–46.CrossRefPubMed

Dong Z, Yang L, Lai D. KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression. Cell Prolif. 2013;46:425–35.CrossRefPubMed

Eligar SM, Pujari R, Swamy BM, Shastry P, Inamdar SR. Sclerotium rolfsii lectin inhibits proliferation and induces apoptosis in human ovarian cancer cell line PA-1. Cell Prolif. 2012;45:397–403.CrossRefPubMed

Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One. 2012;7:e34546.CrossRefPubMedPubMedCentral

Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget. 2014;5:10816–29.CrossRefPubMedPubMedCentral

Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P, et al. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol Med Rep. 2012;5:1277–80.PubMed

Wang L, Wang B, Fang M, Guo F, Cui M. Identification of microRNAs and target genes involved in serous ovarian carcinoma and their influence on survival. Eur J Gynaecol Oncol. 2014;35:655–61.PubMed

Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.

Hirata Y, Murai N, Yanaihara N, Saito M, Urashima M, Murakami Y, et al. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. BMC Cancer. 2014;14:799.CrossRefPubMedPubMedCentral

10.

Cui J, Eldredge JB, Xu Y, Puett D. MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone. PLoS One. 2011;6:e21730.CrossRefPubMedPubMedCentral

11.

Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:3501–8.CrossRef

12.

Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011;15:1593–602.CrossRefPubMedPubMedCentral

13.

Liu N, Zhou C, Zhao J, Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Investig. 2012;30:577–82.CrossRef

14.

Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18:43–54.

15.

Yu X, Li Z, Liu J. Mirnas in primary cutaneous lymphomas. Cell Prolif. 2015.

16.

Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.PubMed

17.

Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48:1–6.CrossRefPubMed

18.

Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013;4:665–76.CrossRefPubMedPubMedCentral

19.

Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4:346–61.CrossRefPubMedPubMedCentral

20.

Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3:44–57.PubMedPubMedCentral

21.

Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y, et al. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One. 2012;7:e39102.CrossRefPubMedPubMedCentral

22.

Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One. 2012;7:e33778.CrossRefPubMedPubMedCentral

23.

Du B, Wang Z, Zhang X, Feng S, Wang G, He J, et al. MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One. 2014;9:e88022.CrossRefPubMedPubMedCentral

24.

Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, et al. Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology. 2014;60:872–83.CrossRefPubMedPubMedCentral

25.

Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015.

26.

Li Z, Yu X, Shen J, Jiang Y. Microrna dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015.

27.

Hecker N, Stephan C, Mollenkopf HJ, Jung K, Preissner R, Meyer HA. A new algorithm for integrated analysis of miRNA-mRNA interactions based on individual classification reveals insights into bladder cancer. PLoS One. 2013;8:e64543.CrossRefPubMedPubMedCentral

28.

Long B, Wang K, Li N, Murtaza I, Xiao JY, Fan YY, et al. miR-761 regulates the mitochondrial network by targeting mitochondrial fission factor. Free Radic Biol Med. 2013;65:371–9.CrossRefPubMedPubMedCentral

29.

Cohen JE, Lee PR, Fields RD. Systematic identification of 3′-UTR regulatory elements in activity-dependent mRNA stability in hippocampal neurons. Philosophical Trans R Soc Lond B Biol Sci. 2014;369.

30.

Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179.CrossRefPubMedPubMedCentral

31.

Wurz K, Garcia RL, Goff BA, Mitchell PS, Lee JH, Tewari M, et al. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer. 2010;49:577–84.PubMedPubMedCentral

32.

Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, et al. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2009;19:641–7.CrossRef

33.

Tang H, Yao L, Tao X, Yu Y, Chen M, Zhang R, et al. MiR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting tln1. Int J Mol Med. 2013;32:381–8.PubMed

34.

Gao C, Han C, Yu Q, Guan Y, Li N, Zhou J, et al. Downregulation of Msi1 suppresses the growth of human colon cancer by targeting p21cip1. Int J Oncol. 2015;46:732–40.PubMed

35.

Liu X, Yang WT, Zheng PS. Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas. Oncotarget. 2014;5:10870–85.CrossRefPubMedPubMedCentral

36.

Gioia U, Di Carlo V, Caramanica P, Toselli C, Cinquino A, Marchioni M, et al. miR-23a and miR-125b regulate neural stem/progenitor cell proliferation by targeting Musashi1. RNA Biol. 2014;11:1105–12.CrossRefPubMedPubMedCentral

37.

Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells. 2014;32:135–44.CrossRefPubMedPubMedCentral

38.

Li D, Peng X, Yan D, Tang H, Huang F, Yang Y, et al. Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer. Ann Surg Oncol. 2011;18:2074–83.CrossRefPubMed

39.

Vo DT, Subramaniam D, Remke M, Burton TL, Uren PJ, Gelfond JA, et al. The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol. 2012;181:1762–72.CrossRefPubMedPubMedCentral

40.

Vo DT, Abdelmohsen K, Martindale JL, Qiao M, Tominaga K, Burton TL, et al. The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res MCR. 2012;10:143–55.CrossRefPubMed

41.

Kuang RG, Kuang Y, Luo QF, Zhou CJ, Ji R, Wang JW. Expression and significance of Musashi-1 in gastric cancer and precancerous lesions. World J Gastroenterol WJG. 2013;19:6637–44.CrossRefPubMed

Titel: miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma
verfasst von: Can Shi
Zhenyu Zhang
Publikationsdatum: 12.11.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4377-z

Neu im Fachgebiet Onkologie

17.04.2024 | Mammakarzinom | Nachrichten

Springer Medizin

miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Differential interference of vitamin D analogs PRI-1906, PRI-2191, and PRI-2205 with the renewal of human colon cancer cells refractory to treatment with 5-fluorouracil

FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target

Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy

CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion

Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs

Overexpression of OCT4 contributes to progression of hepatocellular carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Update Onkologie